Immunosuppressants - Southeast Asia

Southeast Asia

The Immunosuppressants market in Southeast Asia is expected to achieve a revenue of US$401.30m by 2024.
It is projected to experience a compound annual growth rate (CAGR 2024-2028) of 16.48%, leading to a market volume of US$738.80m by 2028.
In terms of global comparison, United States is anticipated to generate the highest revenue of US$33,610.00m in 2024.
In Southeast Asia, the demand for immunosuppressants is on the rise due to an increasing prevalence of autoimmune diseases in the region.

Key regions: Italy, Canada, Australia, France, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The Immunosuppressants market in Southeast Asia has been steadily growing over the years.

Customer preferences: Patients in Southeast Asia prefer Immunosuppressants due to their effectiveness in preventing organ rejection after transplantation. Furthermore, the increasing prevalence of autoimmune diseases and cancer has also contributed to the growth of the market.

Trends in the market: Indonesia and the Philippines are the largest markets for Immunosuppressants in Southeast Asia. The trend in these countries is towards the use of generic Immunosuppressants due to their affordability. In contrast, Singapore and Malaysia prefer branded Immunosuppressants due to their perceived higher quality. The market is also seeing a shift towards biologic Immunosuppressants, which offer better efficacy and fewer side effects compared to traditional Immunosuppressants.

Local special circumstances: In Indonesia, the government has implemented a universal healthcare system, which has increased access to Immunosuppressants for patients. However, the market is still dominated by branded Immunosuppressants due to the lack of trust in generic drugs. In the Philippines, the market is driven by the increasing number of kidney transplantations and the availability of affordable generic Immunosuppressants.

Underlying macroeconomic factors: The growing economies of Southeast Asia have led to increased healthcare spending, which has contributed to the growth of the Immunosuppressants market. However, the market is also affected by the lack of healthcare infrastructure in some countries, which limits access to Immunosuppressants for patients. Additionally, the regulatory environment in Southeast Asia is still evolving, which can lead to delays in the approval of new Immunosuppressants.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.